L
62
2
DVN
16
3
DTE
50
3
XYL
37
2
DE
46
3
MPC
47
3
AMGN
44
5
AIG
38
-4
XOM
47
5
PRU
57
-3
DG
2
-6
BBY
40
3
SCHW
64
2
UPS
41
-4
ALLE
37
5
ZTS
47
2
MDLZ
34
2
T
50
3
HRL
39
15
MKC
56
8
L
62
2
DVN
16
3
DTE
50
3
XYL
37
2
DE
46
3
MPC
47
3
AMGN
44
5
AIG
38
-4
XOM
47
5
PRU
57
-3
DG
2
-6
BBY
40
3
SCHW
64
2
UPS
41
-4
ALLE
37
5
ZTS
47
2
MDLZ
34
2
T
50
3
HRL
39
15
MKC
56
8
Financhill
Back

Fulcrum Therapeutics 10K Form

Sell
32

FULC
Fulcrum Therapeutics

Last Price:
2.99
Seasonality Move:
63.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive FULC News And Ratings

See the #1 stock for the next 7 days that we like better than FULC

FULC Financial Statistics

Sales & Book Value

Annual Sales: $2.81M
Cash Flow: $-19.09M
Price / Cash Flow: 0
Annual Sales: $4.77
Price / Book: 0.64

Profitability

EPS (TTM): -0.31000
Net Income (TTM): $-17.91M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Fulcrum Therapeutics Earnings Forecast

Key Fulcrum Therapeutics Financial Ratios

  • The Research & Development expenses have been 2,559.75% of Revenue.
  • The Net Earning history of FULC is -3,470.05% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 4 years.

Fulcrum Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: FULC
CUSIP: 359616
Website: fulcrumtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FULC Technical Analysis vs Fundamental Analysis

Sell
32
Fulcrum Therapeutics (FULC) is a Sell

Is Fulcrum Therapeutics a Buy or a Sell?